BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22521633)

  • 1. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products.
    Singh S; Handa T; Narayanam M; Sahu A; Junwal M; Shah RP
    J Pharm Biomed Anal; 2012 Oct; 69():148-73. PubMed ID: 22521633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of LC/MS, GC/MS, and LC/NMR hyphenated techniques to identify a drug degradation product in pharmaceutical development.
    Pan C; Liu F; Ji Q; Wang W; Drinkwater D; Vivilecchia R
    J Pharm Biomed Anal; 2006 Feb; 40(3):581-90. PubMed ID: 16242883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
    Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
    J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitive derivatization methods for the determination of genotoxic impurities in drug substances using hyphenated techniques.
    Raman NV; Prasad AV; Reddy KR
    J Pharm Biomed Anal; 2014 Feb; 89():276-81. PubMed ID: 24316427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of hyphenated LC-MS techniques in pharmaceutical analysis.
    Ermer J; Vogel M
    Biomed Chromatogr; 2000 Oct; 14(6):373-83. PubMed ID: 11002275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of pharmaceutical impurities in formulated dosage forms.
    Pan C; Liu F; Motto M
    J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impurity Profile of Bronchodilators used in Asthma: A Critical Review.
    Prajapati KJ; Kothari CS
    Curr Drug Discov Technol; 2018; 15(4):272-304. PubMed ID: 28875855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyphenated techniques and their applications in natural products analysis.
    Sarker SD; Nahar L
    Methods Mol Biol; 2012; 864():301-40. PubMed ID: 22367902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-excipient compatibility testing-Identification and characterization of degradation products of phenylephrine in several pharmaceutical formulations against the common cold.
    Douša M; Gibala P; Havlíček J; Plaček L; Tkadlecová M; Břicháč J
    J Pharm Biomed Anal; 2011 Jul; 55(5):949-56. PubMed ID: 21481557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterization of process-related impurities and degradation products in larotaxel.
    Che X; Shen L; Xu H; Liu K
    J Pharm Biomed Anal; 2011 Jul; 55(5):1190-6. PubMed ID: 21530132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
    Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Impurity Profiling Methods Using Modern Analytical Techniques.
    Ramachandra B
    Crit Rev Anal Chem; 2017 Jan; 47(1):24-36. PubMed ID: 27070830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eliminating pharmaceutical impurities: Recent advances in detection techniques.
    Liu DQ; Sun M; Wu L
    Curr Opin Drug Discov Devel; 2010; 13(6):748-57. PubMed ID: 21061235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations.
    Wu Y
    Biomed Chromatogr; 2000 Oct; 14(6):384-96. PubMed ID: 11002276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of hyphenated LC-MS/MS technique for characterization of impurity profile of quetiapine during drug development.
    Stolarczyk EU; Kutner A
    Acta Pol Pharm; 2010; 67(6):599-608. PubMed ID: 21229874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LC-MS characterization of trace impurities contained in calcium folinate.
    Francese G; Corana F; Meneghetti O; Marazza F
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):757-63. PubMed ID: 15927438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical impurities and degradation products: uses and applications of NMR techniques.
    Maggio RM; Calvo NL; Vignaduzzo SE; Kaufman TS
    J Pharm Biomed Anal; 2014 Dec; 101():102-22. PubMed ID: 24853620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.